Get started
Author

François Somme

Observed names: F. Somme, Francois Somme
Observed institutions: Society of Nuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg, Hôpitaux Universitaires de Strasbourg, Hôpital d'Hautepierre, Institut Strauss, Université de Strasbourg
ORCID: 0000-0002-1158-7076
Observed ORCID: 0000-0002-1158-7076
OpenAlex ID: A5068202335
Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature
2020 · François Somme, Laura Bender, et al. · Cancer Imaging · 39
PDF
Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?
2024 · Eric Ouvrard, Ashjan Kaseb, et al. · Frontiers in Medicine · 31
PDF
High risk of recurrence for grade II meningioma: a 10-year multicenter analysis of prognosis factors
2021 · Laura Bender, François Somme, et al. · Chinese Clinical Oncology · 24
PDF
Metabolomic Profile of Aggressive Meningiomas by Using High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance
2019 · Laura Bender, François Somme, et al. · Journal of Proteome Research · 21
Solid pseudopapillary tumour should be part of differential diagnosis of focal pancreatic lesions with increased 18F‐FDOPA uptake
2020 · François Somme, Marie‐Soline Montaz‐Rosset, et al. · Clinical Endocrinology · 11
Evaluation of Oxalate Osteopathy Secondary to Hyperoxaluria With 18F-FDG PET/CT and 99mTc-HMDP Bone Scan
2018 · François Somme, Cyrille Blondet, et al. · Clinical Nuclear Medicine · 5
A Hangover Under 177Lu-PSMA-617 Therapy: A Red Flag for Brain 68Ga-PSMA-11 PET/MRI?
2024 · Nathan Poterszman, Laura Somme, et al. · Clinical Nuclear Medicine · 4
Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [177Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer
2025 · Nathan Poterszman, Cécile Hammer-Lefevre, et al. · Theranostics · 3
A bicentric retrospective study of the correlation of EAU BCR risk groups with 18F-PSMA-1007 PET/CT detection in prostate cancer biochemical recurrence
2024 · Nathan Poterszman, Charles Merlin, et al. · Scientific Reports · 3
Real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in France.
2024 · Guilhem Roubaud, François Somme, et al. · Journal of Clinical Oncology · 3
PDF
18F-FDG PET/CT Monitoring of Tumor Response to Tyrosine Kinase Inhibitors and Alkylating Drugs in an SDH-Deficient GIST
2021 · François Somme, Laura Bender, et al. · Clinical Nuclear Medicine · 3
Complete Response of a Pleural, Hepatic, and Splenic Metastatic Primary Breast Angiosarcoma Using Gemcitabine Monotherapy
2020 · Laura Bender, Justine Gantzer, et al. · JCO Oncology Practice · 3
PDF
Efficiency of Nivolumab Considering Size of Tumor Thrombus in a Case of Metastatic Clear Cell Renal Cell Carcinoma with an Extensive Right Atrial Tumor Thrombus: A Case Report
2019 · Laura Bender, Justine Gantzer, et al. · 2
Analyse descriptive de la plus grande cohorte mondiale de patients atteints de CPRCm traités en accès précoce par [177Lu]Lu-PSMA-617
2025 · S. Girault, G. Roubaud, et al. · Médecine Nucléaire · 1
1814P First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France
2023 · A-L. Giraudet, P. Olivier, et al. · Annals of Oncology · 1
PDF
Impact of pelvic dynamic acquisition on final reading of 18F‐Fluorocholine positron emission tomography in patients with prostate adenocarcinoma: True need or unnecessary burden?
2021 · Adrien Latge, Céline Heimburger, et al. · Journal of Medical Imaging and Radiation Oncology · 1
TEP à la 18F-FCH couplée à la TDM triphasique dans le bilan préopératoire de l’hyperparathyroïdie primaire
2020 · V. Pretet, M. Rotania, et al. · Médecine Nucléaire · 1
Real-World Outcomes of [ 177 Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer
2026 · Clément Bailly, Lavinia Vija, et al. · Journal of Nuclear Medicine
Prognostic value of [18F]FDG PET/CT and PERCIST criteria in patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan
2026 · Juliette Frega, Laura Somme, et al. · European Journal of Nuclear Medicine and Molecular Imaging
PDF
Gravity versus pump-driven infusion in targeted radionuclide therapy: a model-based dosimetric evaluation of extravasation
2026 · Olivia Lienhardt, Oreste Allegrini, et al. · EJNMMI Physics
[177Lu]Lu-PSMA extravasation: from quantitative imaging to clinical guidelines
2026 · Julien Salvadori, Oreste Allegrini, et al. · Physics in Medicine and Biology
Pharmacokinetics and dosimetry of lutetium Lu 177 zadavotide guraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the ECLIPSE sub-study.
2026 · Frankis Almaguel, Antony Kelly, et al. · Journal of Clinical Oncology
Évaluation du rôle pronostique de la TEP-TDM au 18F-FDG chez les patientes atteintes d’un cancer du sein métastatique HER2-low traitées par trastuzumab-deruxtecan
2026 · J. Frega, L. Somme, et al. · Médecine Nucléaire
Retraitement par [177Lu]Lu-PSMA-617 chez des patients atteints d’un CPRCm traités dans le cadre d’un accès précoce
2026 · P. Robin, P. Barthelemy, et al. · Médecine Nucléaire
Retraitement par [177Lu]Lu-PSMA-617 chez des patients atteints d’un cancer de la prostate métastatique résistant à la castration (CPRCm) traités dans le cadre du programme d’accès précoce
2025 · F. Somme, P. Robin, et al. · Progrès en Urologie - FMC
Works count: 34
Citation count: 156
H-index: 5
I10-index: 5
Year
Topic
Type